# Secondary Databased Post-marketing Surveillance Study of BNT162b2

> **NCT06743334** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Tozinameran (BNT162b2)
- **BIOLOGICAL:** Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
- **BIOLOGICAL:** Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

## Key facts

- **NCT ID:** NCT06743334
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-23
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06743334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06743334, "Secondary Databased Post-marketing Surveillance Study of BNT162b2". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06743334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*